Tel:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@anticorps-enligne.fr

PRAME Protéine

PRAME Origine: Humain Hôte: Escherichia coli (E. coli) Recombinant > 98 % by SDS-PAGE. Visualized by silver stain
N° du produit ABIN1589783
  • Antigène Voir toutes PRAME Protéines
    PRAME (Preferentially Expressed Antigen in Melanoma (PRAME))
    Type de proteíne
    Recombinant
    Origine
    Humain
    Source
    • 4
    • 2
    • 1
    • 1
    • 1
    Escherichia coli (E. coli)
    Séquence
    MNPLETLSIT NCRLSEGDVM HLSQSPSVSQ LSVLSLSGVM LTDVSPEPLQ ALLERASATL QDLVFDECGI TDDQLLALLP SLSHCSQLTT LSFYGNSISI
    Attributs du produit
    Length (AA): 106
    Pureté
    > 98 % by SDS-PAGE. Visualized by silver stain
    Top Product
    Discover our top product PRAME Protéine
  • Indications d'application
    Positive control for WB.
    Commentaires

    Cytokines & Growth Factors

    Restrictions
    For Research Use only
  • Format
    Lyophilized
    Reconstitution
    Human PRAME should be reconstituted in water to a concentration of 0.1 mg/mL. This solution can be diluted in water or other buffer solutions or stored at -20 °C
    Buffer
    10 mM Tris, 25 mM NaP, pH 7.4
    Stock
    0 °C
    Stockage commentaire
    The lyophilized human PRAME, though stable at room temperature, is best stored desiccated below 0 °C. Reconstituted human PRAME should be stored in working aliquots at -20 °C.
  • Antigène
    PRAME (Preferentially Expressed Antigen in Melanoma (PRAME))
    Autre désignation
    PRAME (PRAME Produits)
    Synonymes
    PRAME Protein, CT130 Protein, MAPE Protein, OIP-4 Protein, OIP4 Protein, 4930534P07Rik Protein, preferentially expressed antigen in melanoma Protein, PRAME Protein, Prame Protein
    Sujet
    PRAME/MAPE/OIP4 is a germinal tissue-specific gene that is also expressed at high levels in haematological malignancies and solid tumors. The physiological functions of PRAME in normal and tumor cells are unknown, although a role in the regulation of retinoic acid signaling has been proposed. Sequence homology and structural predictions suggest that PRAME is related to the Leucine-rich repeat (LRR) family of proteins, which have diverse functions. PRAME, or „preferentially expressed antigen in melanoma”, was originally identified as a gene encoding a HLA-A24 restricted antigenic peptide presented to autologous tumor-specific cytotoxic T lymphocytes derived from a patient with melanoma. PRAME is synonymous with MAPE (melanoma antigen preferentially expressed in tumors) and OIP4 (OPA-interacting protein 4), and its expression profile defines it as a cancer-testis antigen. Cancer-testis antigens (CTAs) are encoded by non-mutated genes expressed at high levels in germinal tissues and tumors, but which are absent from or detected at low levels in other tissues. PRAME may be somewhat different to other cancer-testis antigens in that it shows some expression in normal tissues such as ovary, adrenal, placenta and endometrium. The C-terminus of human PRAME (amino acids 453-509) was also identified to bind Neisseria gonorrhoeae opacity factors, in this case the OPA-P protein. Thus PRAME is also known as OIP4 (OPA interacting protein), although the functional implications of the interaction are unknown.
    Synonyms: Melanoma antigen preferentially expressed in tumors, Opa-interacting protein 4, MAPE, OIP4
    Poids moléculaire
    10.7 kDa
    NCBI Accession
    NM_006115, NP_006106
    UniProt
    P78395
    Pathways
    Retinoic Acid Receptor Signaling Pathway, Nuclear Hormone Receptor Binding
Vous êtes ici:
Support technique